L4545

L-798106

≥98% (HPLC)

• Synonym(e): (2E)-N-[(5-bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide
• Empirische Formel (Hill-System): C₂₇H₂₂BrNO₄S
• CAS-Nummer: 244101-02-8
• Molekulargewicht: 536.44
• MDL-Nummer: MFCD08272644
• UNSPSC-Code: 12352204
• PubChem Substanz-ID: 329817411
• NACRES: NA.77

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: powder
• Löslichkeit: DMSO: >20 mg/mL
• Ersteller: Merck & Co., Inc., Kenilworth, NJ, U.S.
• Lagertemp.: 2-8°C
• SMILES String: COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c2ccccc2Cc3ccc4ccccc4c3
• InChI: 1S/C27H22BrNO4S/c1-33-25-14-13-24(28)18-26(25)34(31,32)29-27(30)15-12-21-7-3-5-9-23(21)17-19-10-11-20-6-2-4-8-22(20)16-19/h2-16,18H,17H2,1H3,(H,29,30)/b15-12+
• InChIKey: ODTKFNUPVBULRJ-NTCAYCPXSA-N

Beschreibung

Anwendung

L-798106, a selective prostanoid receptor EP3 antagonist, is used in prostanoid receptor signaling studies that regulate COX-2 levels and the central excitatory effects of PGE(2) on PVN neurons.

Biochem./physiol. Wirkung

L-798106 was among the first prostanoid receptor EP3-selective antagonists. It has been used in multiple studies to tease out EP3 agonist activity, both in vitro and in vivo. It successfully blocks the actions of sulprostone, an EP3-selective agonist, and it helped show that the vascular contraction effect of PGE₂ is due to its prostanoid EP3 agonist activity.

Leistungsmerkmale und Vorteile

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• H-Sätze: H413
• P-Sätze: P273 - P501
• Gefahreneinstufungen: Aquatic Chronic 4
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable